Medicinal Products

Dáil Éireann Debate, Wednesday - 20 May 2026

• Debates
• Find a debate
  • Dáil debates
  • Seanad debates
  • Committee debates
• Find a vote
  • Dáil votes
  • Seanad votes
  • Committee votes
• Parliamentary questions
  • Written questions
  • Oral questions
• Search tips
• Utterances having an adverse effect

Wednesday, 20 May 2026

Questions (286)

Barry Heneghan

Question:

286. Deputy Barry Heneghan asked the Minister for Health the timeline for a decision by the HSE drugs group regarding the reimbursement of risdiplam for adults living with spinal muscular atrophy (SMA) (details supplied); when an outcome from the HSE drugs group is expected; and if she will make a statement on the matter. [38237/26]

Written answers

Minister for Health

Under the Health (Pricing and Supply of Medical Goods) Act 2013, the HSE has statutory responsibility for decisions on the pricing and reimbursement of medicines and medical devices; therefore, the matter has been referred to the HSE for attention and direct reply to the Deputy.

• Previous Answer
• Next Answer